Modeling and simulation of preclinical cardiac safety: Towards an integrative framework

Drug Metabolism and Pharmacokinetics

Volumn 24, Issue 1, 2009, Pages 76-90

  Soubret, Antoine ^a   Helmlinger, Gabriel ^b   Dumotier, Bérengère ^a   Bibas, Ruben ^a   Georgieva, Anna ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

Computational models; Computer modeling and simulation; Heart; Mathematical modeling; Mechanism; Organ; Pharmacodynamic modeling; Pharmacokinetic; Physiologically based modeling; Species differences

Indexed keywords

NEW DRUG;

DRUG APPROVAL; DRUG MARKETING; DRUG SAFETY; DRUG SCREENING; EXPERIMENTAL MODEL; HEART ELECTROPHYSIOLOGY; HEART VENTRICLE ARRHYTHMIA; MATHEMATICAL MODEL; QT INTERVAL; REVIEW; RISK ASSESSMENT; SPECIES DIFFERENCE; TORSADE DES POINTES;

EID: 67649360009     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.24.76     Document Type: Review

References (153)

1. Libby, P., Bonow, R. O., Mann, D. L. and Zipes, D. P.: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 8th ed., Saunders (2008).
2. Fossa, A. A., Wisialowski, T., Crimin, K., Wolfgang, E., Couderc, J. P., Hinterseer, M., Kaab, S., Zareba, W., Badilini, F. and Sarapa, N.: Analyses of dynamic Beat-to-Beat QT-TQ interval (ECG restitution) changes in humans under normal sinus rhythm and prior to an event of Torsades de Pointes during QT prolongation caused by Sotalol. Annals of Noninvasive Electrocardiology, 12(4): 338-348 (2007).
3. Hondeghem, L. M.: Thorough QT/QTc not so thorough: Removes torsadogenic predictors from the T-wave, incriminates safe drugs, and misses profibrillatory drugs. Journal of Cardiovascular Electrophysiology, 17(3): 337-340 (2006).
4. Hondeghem, L. M.: Use and abuse of QT and TRIaD in cardiac safety research: Importance of study design and conduct. European Journal of Pharmacology, 584(1): 1-9 (2008).
5. Hondeghem, L. M.: QT and TdP-QT: an unreliable predictor of proarrhythmia. Acta Cardiologica, 63(1): 1-7 (2008).
6. Roden, D. M.: Long-QT syndrome. New England Journal of Medicine, 358(2): 169-176 (2008).
7. Shah, R. R.: Drug-induced prolongation of the QT interval: why the regulatory concern? Fundamental & Clinical Pharmacology, 16(2): 119-124 (2002).
8. Shah, R. R.: Drug-induced QT dispersion: does it predict the risk of Torsade de Pointes?, 38(1): 10-18 (2005).
9. Thomsen, M. B., Matz, J., Volders, P. G. A, and Vos,M. A.: Assessing the proarrhythmic potential of drugs: Current status of models and surrogate parameters of torsades de pointes arrhythmias. Pharmacology & Therapeutics, 112(1): 150-170 (2006).
10. Belardinelli, L., Antzelevitch, C. and Vos, M. A.: Assessing predictors of drug-induced torsade de pointes. Trends in Pharmacological Sciences, 24(12): 619-625 (2003).
11. Zipes, D. and Jalife, J.: Cardiac Electrophysiology: From Cell to Bedside. 4th ed., Saunders (2004).
12. Friedrichs, G. S., Patmore, l. and Bass, A.: Non-clinical evaluation of ventricular repolarization (ICHS7b): results of an interim survey of international pharmaceutical companies. J Pharmacol Toxicol Methods, 52(1): 6-11 (2005).
13. Cavero, I. and Crumb, W.: Moving towards better predictors of drug-induced Torsade de Pointes-2-3 November 2005, Crystal City, Virginia, USA. Expert Opinion on Drug Safety, 5(2): 335-340 (2006).
14. Drolet, B., Zhang, S. T., Deschenes, D., Rail, J., Nadeau, S., Zhou, Z. G., January, C. T. and Turgeon, J.: Droperidol lengthens cardiac repolarization due to block of the rapid component of the delayed rectifier potassium current. Journal of Cardiovascular Electrophysiology, 10(12): 1597-1604 (1999;).
15. Salata, J. J., Jurkiewicz, N. K., Wallace, A. A., Stupienski, R. F., Guinosso, P. J and, Lynch, J. J.: Cardiac Electrophysiological Actions of the Histamine H-1-Receptor Antagonists Astemizole and Terfenadine Compared with Chlorpheniramine and Pyrilamine. Circulation Research, 76(1): 110-119 (1995).
16. Sanguinetti, M. C. and Jurkiewicz, N. K.: 2 Components of Cardiac Delayed Rectifier K+Current-Differential Sensitivity to Block by Class-Iii Antiarrhythmic Agents. Journal of General Physiology, 96(1): 195-215 (1990).
17. Hancox, J. C., Mcpate, M. J., El Harchi, A. and Zhang, Y. H.: The hERG potassium channel and hERG screening for drug-induced torsades de pointes. Pharmacology & Therapeutics, 119(2): 118-132 (2008).
18. Helliwell, R.: Recording hERG Potassium Currents adb Assessing the Effects of Compounds Using the Whole-Cell Patch-Clamp Technique. Methods Mol. Biol., 491: 279-295 (2009).
19. Sanguinetti, M. and Mitcheson, J. S.: Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci., 26(3): 119-124 (2005).
20. Thomas, D., Karle, C. A. and Kiehn, J.: The cardiac hERG/I-Kr potassium channel as pharmacological target: Structure, function, regulation, and clinical applications. Current Pharmaceutical Design, 12(18): 2271-2283 (2006).
21. Traebert, M., Dumotier, B., Meister, L., Hoffmann, P., Dominguez Estevez, M. and Suter, W.: Inhibition of hERG K+currents by antimalarial drugs in stably transfected HEK293 cells. European Journal of Pharmacology, 484(1): 41-48 (2004).
22. Witchel, H. J., Milnes, J. T., Mitcheson, J. S. and Hancox, J. C.: Troubleshooting problems with in vitro screening of drugs for QT interval prolongation using HERG K+channels expressed in mammalian cell lines and Xenopus oocytes. Journal of Pharmacological and Toxicological Methods, 48(2):65-80 (2002).
23. Gintant, G. A.: Preclinical Torsades-de-Pointes screens: Advantages and limitations of surrogate and direct approaches in evaluating proarrhythmic risk. Pharmacology & Therapeutics, 119(2): 199-209 (2008).
24. Guth, B. D.: Preclinical cardiovascular risk assessment in modern drug development. Toxicological Sciences, 97(1): 4-20 (2007).
25. Milberg, P., Reinsch, N., Osada, N., Wasmer, K., Monnig, G., Stypmann, J., Breithardt, G., Haverkamp, W. and Eckardt, L.: Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early after-depolarizations in an intact heart model of LQT3. Basic Research in Cardiology, 100(4): 365-371 (2005).
26. Redfern, W. S., Carlsson, L., Davis, A. S., Lynch, W. G., MacKenzie, I., Palethorpe, S., Siegl, P. K. S., Strang, I., Sullivan, A. T., Wallis, R., Camm, A. J. and Hammond, T. G.: Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovascular Research, 58(1): 32-45 (2003).
27. Yan, G. X., Shimizu, W. and Antzelevitch, C.: Characteristics and distribution of M cells in arterially perfused canine left ventricular wedge preparations. Circulation, 98(18): 1921-1927 (1998).
28. Yan, G. X., Rials, S. J., Wu, Y., Liu, T. X., Xu, X. P., Marinchak, R. A. and Kowey, P. R.: Ventricular hypertrophy amplifies transmural dispersion of repolarization and induces phase 2 early after depolarization. Circulation, 104(17): 116 (2001).
29. Antzelevitch, C.: Transmural dispersion of repolarization and the T wave. Cardiovascular Research, 50(3): 426-431 (2001).
30. Cranefield, P. F. and Hoffman, B. F.: Conduction of the cardiac impulse. Circ Res, 28(2): 199-233 (1971).
31. Hondeghem, L. M., Carlsson, L. and Duker, G.: Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation, 103(15): 2004-2013 (2001).
32. Franz, M. R.: Current status of monophasic action potential recording: theories, measurements and interpretations. Cardiovascular Research, 41(1): 25-40 (1999).
33. Dumotier, B. M., Deurinck, M., Yang, Y., Traebert, M. and Suter, W.: Relevance of in vitro SCREENIT results for drug-induced QT interval prolongation in vivo: A database review and analysis. Pharmacology & Therapeutics, 119(2): 152-159 (2008).
34. Wang, J. L., Urban, L. and Bojanic, D.: Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opinion on Drug Metabolism & Toxicology, 3(5): 641-665 (2007).
35. Hondeghem, L. M., Lu, H. R., van Rossem, K. and De Clerck, F.: Detection of proarrhythmia in the female rabbit heart: Blinded validation. Journal of Cardiovascular Electrophysiology, 14(3): 287-294 (2003).
36. Hondeghem, L. M. and Hoffmann, P.: Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: Importance of triangulation, reverse use dependence, and instability. Journal of Cardiovascular Pharmacology, 41(1): 14-24 (2003).
37. Lawrence, C. L., Pollard, C. E., Hammond, T. G. and Valentin, J. P.: In vitro models of proarrhythmia. British Journal of Pharmacology, 154(7): 1516-1522 (2008).
38. Lu, H. R., Vlaminickx, E., Van de Water, A., Rohrbacker, J., Hermans, A. and Gallacher, D. J.: In-vitro experimental models for the risk assessment of antibiotic-induced QT prolongation. Eur. J. Pharmacol, 577(1-3): 222-332 (2007).
39. Chen, X., Cordes, J. S., Bradley, J. A. and Sun, Zhou, J.: Use of arterially perfused rabbit ventricular wedge in predicting arrhythmogenic potentials of drugs. J. Pharmacol Toxicol Methods, 54(3): 261-272 (2006).
40. ICH Expert Working Group.: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs: E14. 2005 May 12; Geneva, Switzerland. (2005).
41. Fenichel, R. R., Malik, M., Antzelevitch, C., Sanguinetti, M., Roden, D. M., Priori, S. G., Ruskin, J. N., Lipicky, R. J. and Cantilena, L. R.: Drug-induced Torsades de Pointes and implications for drug development. Journal of Cardiovascular Electrophysiology, 15(4): 475-495 (2004).
42. Tsong, Y., Zhong, J. L. and Chen, W. J.: Validation testing in thorough QT/QTc clinical trials. Journal of Biopharmaceutical Statistics, 18(3): 529-541 (2008).
43. Hnatkova, K., Gang, Y., Batchvarov, V. N. and Malik, M.: Precision of QT interval measurement by advanced electrocardiographic equipment. Pace-Pacing and Clinical Electrophysiology, 29(11): 1277-84 (2006).
44. Mclaughlin, N. B., Campbell, R. W. F. and Murray, A.: Comparison of Automatic QT Measurement Techniques in the Normal 12-Lead Electrocardiogram. British Heart Journal, 74(1): 84-89 (1995).
45. Savelieva, I., Yi, G., Guo, X. H., Hnatkova, K. and Malik, M.: Agreement and reproducibility of automatic versus manual measurement of QT interval and QT dispersion. American Journal of Cardiology, 81(4): 471-477 (1998).
46. Darpo, B., Agin, M., Kazierad, D. J., Layton, G., Muirhead, G., Gray, P. and Jorkasky, D. K.: Man versus machine: Is there an optimal method for QT measurements in thorough QT studies? Journal of Clinical Pharmacology, 46(6): 598-612 (2006).
47. Charbit, B., Samain, E., Merckx, P. and Funck-Brentano, C:. QT interval measurement-Evaluation of automatic QTc measurement and new simple method to calculate and interpret corrected QT interval. Anesthesiology, 104(2): 255-260 (2006).
48. Malik, M.: Errors and misconceptions in ECG measurement used for the detection of drug induced QT interval prolongation. Journal of Electrocardiology, 37: 25-33 (2004).
49. Ahnve, S.: Correction of the QT Interval for Heart-Rate-Review of Different Formulas and the Use of Bazetts Formula in Myocardial-Infarction. American Heart Journal, 109(3): 568-574 (1985).
50. Malik, M.: Problems of heart rate correction in assessment of drug-induced QT interval prolongation. Journal of Cardiovascular Electrophysiology, 12(4): 411-420 (2001).
51. Malik, M., Farbom, P., Batchvarov, V., Hnatkova, K. and Camm, A. J.: Relation between QT and RR intervals is highly individual among health subjects: implications for heart rate correction of the QT interval. Heart, 87(3): 220-228 (2002).
52. Malik, M., Hnatkova, K. and Batchvarov, V.: Differences between study-specific and subject-specific heart rate corrections of the QT interval in investigations of drug induced QTc prolongation. Pace-Pacing and Clinical Electrophysiology, 27(6): 791-800 (2004).
53. Orihashi, Y.: Study design, statistical analysis and interpretation of QT prolonging effects in ICH-E14. Journal of Pharmacological Sciences, 106: 27P (2008).
54. Couderc, J. P., Xia, X. J., Zareba, W. and Moss, A. J.: Assessment of the stability of the individual-based correction of QT interval for heart rate. Annals of Noninvasive Electrocardiology, 10(1): 25-34 (2005).
55. Piotrovsky, V.: Pharmacokinetic-pharmacodynamic modeling in the data analysis and interpretation of drug-induced QT/QTc prolongation. Aaps Journal, 7(3): E609-E624 (2005).
56. Garnett, C. E., Beasley, N., Bhattaram, V. A., Jadhav, P. R., Madabushi, R., Stockbridge, N., Tornoe, C. W., Wang, Y., Zhu, H. and Gobburu, J. V.: Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. Journal of Clinical Pharmacology, 48: 13-18 (2008).
57. Bloomfield, D. and Krishna, R.: Commentary on the clinical relevance of concentration/QTc relationships for new drug candidates. Journal of Clinical Pharmacology, 48: 6-8 (2008).
58. Tsong, Y., Shen, M., Zhong, J. and Zhang, J.: Statistical issues of QT prolongation assessment based on linear concentration modeling. Journal of Biopharmaceutical Statistics, 18(3): 564-84 (2008).
59. Pueyo, E., Smetana, P., Laguna, P. and Malik, M.: Estimation of the QT/ RR hysteresis lag. Journal of Electrocardiology, 36: 187-290 (2003).
60. Ahmad, K. and Dorian, P.: Drug-induced QT prolongation and proarrhythmia: an inevitable link? Europace, 9: 16-22 (2007).
61. Hoffmann, P. and Warner, B.: Are hERG channel inhibition and QT interval prolongation all there is in drug-induced torsadogenesis? A review of emerging trends. Journal of Pharmacological and Toxicological Methods, 53(2): 87-105 (2006).
62. Malik, M.: Assessment of drug-induced QT prolongation: To bin or not to bin? Clinical Pharmacology & Therapeutics, 77(4): 241-246 (2005).
63. Roden, D. M.: Drug therapy: Drug-induced prolongation of the QT interval. New England Journal of Medicine, 350(10): 1013-1022 (2004).
64. Shah, R. R.: Drug-induced QT interval prolongation: regulatory perspectives and drug development. Annals of Medicine, 36: 47-52 (2004).
65. Shah, R. R. and Hondeghem, L. M.: Refining detection of drug-induced proarrhythmia: QT interval and TRIaD. Heart Rhythm, 2(7): 758-72 (2005).
66. Morganroth, J.: Cardiac repolarization and the safety of new drugs defined by electrocardiography. Clinical Pharmacology & Therapeutics, 81(1): 108-113 (2007).
67. Yan, G. X. and Antzelevitch, C.: Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation, 98(18): 1928-1936 (1998).
68. Hondeghem, L. M.: Relative contributions of TRIaD and QT to proarrhythmia. Journal of Cardiovascular Electrophysiology, 18(6): 655-657 (2007).
69. Couderc, J. P., Zareba, W., Burattini, L. and Moss, A. J.: Beat-to-beat repolarization variability in LQTS patients with the SCN5A sodium channel gene mutation. Pace-Pacing and Clinical Electrophysiology, 22(11): 1581-1592 (1999).
70. Couderc, J. P., Zareba, W., Moss, A. J., Sarapa, N., Morganroth, J. and Darpo, B.: Identification of sotalol-induced changes in repolarization with T wave area-based repolarization duration parameters. Journal of Electrocardiology, 36: 115-120 (2003).
71. Antzelevitch, C., Sicouri, S., Di Diego, J. M., Burashnikov, A., Viskin, S., Shimizu, W., Yan, G. X., Kowey, P. and Zhang, L.: Does T-peak-T-end provide an index of transmural dispersion of repotarization? Heart Rhythm, 4(8): 1114-1116 (2007).
72. Fossa, A. A., Wisialowski, T. and Crimin, K.: QT prolongation modifies dynamic restitution and hysteresis of the beat-to-beat QT-TQ interval relationship during normal sinus rhythm under varying states of repolarization. Journal of Pharmacology and Experimental Therapeutics, 316(2): 498-506 (2006).
73. Hinterseer, M., Thomsen,M. B., Beckmann, B.M., Pfeufer, A., Schimpf, R., Wichmann, H. E., Steinbeck, G., Vos, M. A. and Kaab, S.: Beat-to-beat variability of QT intervals is increased in patients with drug-induced long-QT syndrome: a case control pilot study. European Heart Journal, 29(2): 185-190 (2008).
74. Fossa, A. A.,Wisialowski, T., Magnano, A.,Wolfgang, E., Winslow, R., Gorczyca, W., Crimin, K. and Raunig, D. L.: Dynamic beat-to-beat Modeling of the QT-RR interval relationship: Analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. Journal of Pharmacology and Experimental Therapeutics, 312(1): 1-11 (2005).
75. Jalife, J., Delmar, M., Davidenko, J., Anumonwo, J. and Kalifa, J.: Basic Cardiac Electrophysiology for the Clinician. 1st ed. Wiley-Blackwell, 1999.
76. Gulrajani, R. M.: Bioelectricity and Biomagnetism. 1st ed. John Wiley & Sons, 1998.
77. Malmivuo, J. and Plonsey, R.: Bioelectromagnetism: Principles and Applications of Bioelectric and Biomagnetic Fields. 1st ed. Oxford University Press, 1995.
78. Plonsey, R. and Barr, R. C.: Bioelectricity: A Quantitative Approach. 3rd ed. Springer, 2007.
79. Sachse, F. B.: Computational Cardiology: Modeling of Anatomy, Electrophysiology, and Mechanics. 1st ed. Springer, 2004.
80. Pullan, A. J.: Mathematically Modeling the Electrical Activity of the Heart: From Cell to Body Surface and Back. 1st ed. World Scientific Publishing Company, 2005.
81. Sundnes, J., Terje, Lines, G., Cai, X., Nielsen, B. F., Mardal, K. A. and Tveito, A.: Computing the Electrical Activity in the Heart. 1st ed. Springer, 2006.
82. Belik, M. E., Usyk, T. P. and McCulloch, A. D.: Computationals method for cardiac electrophysiology. In Ayache, N. (ed.): Computational Models for the Human Body. Elsevier B.V., 2004, pp. 129-188.
83. Benson, A. P., Aslanidi, O. V., Zhang, H. and Holden, A. V.: The canine virtual ventricular wall: A platform for dissecting pharmacological effects on propagation and arrhythmogenesis. Progress in Biophysics & Molecular Biology, 96(1-3): 187-208 (2008).
84. Clayton, R. H. and Panfilov, A. V.: A guide to modelling cardiac electrical activity in anatomically detailed ventricles. Progress in Biophysics & Molecular Biology, 96(1-3): 19-43 (2008).
85. Holden, A. V., Aslanidi, O. V., Benson, A. P., Clayton, R. H., Halley, G., Li, P. and Tong, W. C.: The virtual ventricular wall: A tool for exploring cardiac propagation and arrhythmogenesis. Journal of Biological Physics, 32(3-4): 355-368 (2006).
86. Hunter, P. J. and Borg, T. K.: Integration from proteins to organs: the Physiome Project. Nature Reviews Molecular Cell Biology, 4(3): 237-243 (2003).
87. Hunter, P. J., Crampin, E. J. and Nielsen, P. M. F.: Bioinformatics, multiscale modeling and the IUPS physiome project. Briefings in Bioinformatics, 9(4): 333-343 (2008).
88. Kleber, A. G. and Rudy, Y.: Basic mechanisms of cardiac impulse propagation and associated arrhythmias. Physiological Reviews, 84(2): 431-488 (2004).
89. Muzikant, A. L. and Penland, R. C.: Models for profiling the potential QT prolongation risk of drugs. Current Opinion in Drug Discovery & Development, 5(1): 127-135 (2002).
90. Noble, D., Levin, J. and Scott, W.: Biological simulations in drug discovery. Drug Discovery Today, 4(1): 10-66 (1999).
91. Noble, D. and Rudy, Y.: Models of cardiac ventricular action potentials: iterative interaction between experiment and simulation. Philosophical Transactions of the Royal Society of London Series A-Mathematical Physical and Engineering Sciences, 359(1783): 1127-42 (2001).
92. Noble, D.: Modelling the heart: insights, failures and progress. Bioessays, 24(12): 1155-63 (2002).
93. Noble, D.: Unraveling the genetics and mechanisms of cardiac arrhythmia. Proceedings of the National Academy of Sciences of the United States of America, 99(9): 5755-5756 (2002).
94. Noble, D.: Will genomics revolutionise pharmaceutical R&D? Trends in Biotechnology, 21(8): 333-337 (2003).
95. Noble, D.: Modelling the heart. Physiology, 19: 191-197 (2004).
96. Noble, D.: From the Hodgkin-Huxley axon to the virtual heart. Journal of Physiology-London, 580(1): 15-22 (2007).
97. Noble, D.: Computational models of the heart and their use in assessing the actions of drugs. Journal of Pharmacological Sciences, 107(2): 107-117 (2008).
98. Rudy, Y. and Silva, J. R.: Computational biology in the study of cardiac ion channels and cell electrophysiology. Quarterly Reviews of Biophysics, 39(1): 57-116 (2006).
99. Trayanova, N., Plank, G. and Rodriguez, B.: What have we learned from mathematical models of defibrillation and postshock arrhythmogenesis? Application of bidomain simulations. Heart Rhythm, 3(10): 1232-1235 (2006).
100. Trayanova, N.: Defibrillation of the heart: insights into mechanisms from modelling studies. Experimental Physiology, 91(2): 323-337 (2006).
101. Weiss, J. N., Qu, Z. L., Chen, P. S., Lin, S. F., Karagueuzian, H. S., Hayashi, H., Garfinkel, A. and Karma, A.: The dynamics of cardiac fibrillation. Circulation, 112(8): 1232-1240 (2005).
102. Weiss, J. N., Karma, A., Shiferaw, Y., Chen, P. S., Garfinkel, A. and Qu, Z.: From pulsus to Pulseless the saga of cardiac alternans. Circulation Research, 98(10): 1244-1253 (2006).
103. Winslow, R. L., Scollan, D. F., Holmes, A., Yung, C. K., Zhang, J. and Jafri, M. S.: Electrophysiological modeling of cardiac ventricular function: From cell to organ. Annual Review of Biomedical Engineering, 2: 119-+ (2000;).
104. Hodgkin, A. L. and Huxley, A. F.: A Quantitative Description of Membrane Current and Its Application to Conduction and Excitation in Nerve. Journal of Physiology-London, 117(4): 500-544 (1952).
105. Noble, D.: Modification of Hodgkin-Huxley Equations Applicable to Purkinje Fibre Action and Pace-Maker Potentials. Journal of Physiology-London, 160(2): 317-352 (1962).
106. Beeler, G. W. and Reuter, H.: Reconstruction of Action Potential of Ventricular Myocardial Fibers. Journal of Physiology-London, 268(1): 177-210 (1977).
107. Luo, C. H. and Rudy, Y.: A Dynamic-Model of the Cardiac Ventricular Action-Potential.1. Simulations of Ionic Currents and Concentration Changes. Circulation Research, 74(6): 1071-1096 (1994).
108. Luo, C. H. and Rudy, Y.: A Model of the Ventricular Cardiac Action-Potential-Depolarization, Repolarization, and Their Interaction. Circulation Research, 68(6): 1501-1526 (1991).
109. Zeng, J. L. and Rudy, Y.: Early Afterdepolarizations in Cardiac Myocytes-Mechanism and Rate Dependence. Biophysical Journal, 68(3): 949-964 (1995).
110. Viswanathan, P. C., Shaw, R. M. and Rudy, Y.: Effects of I-Kr and I-Ks heterogeneity on action potential duration and its rate dependence-A simulation study. Circulation, 99(18): 2466-2474 (1999).
111. Shaw, R. M. and Rudy, Y.: Electrophysiologic effects of acute myocardial ischemia: a theoretical study of altered cell excitability and action potential duration. Cardiovascular Research, 35(2): 256-272 (1997).
112. Faber, G. M. and Rudy, Y.: Action potential and contractility changes in [Na+](i) overloaded cardiac myocytes: A simulation study. Biophysical Journal, 78(5): 2392-2404 (2000;).
113. Potse, M., Dube, B., Richer, J., Vinet, A. and Gulrajani, R. M.: A comparison of monodomain and bidomain reaction-diffusion models for action potential propagation in the human heart. IEEE Transactions on Biomedical Engineering, 53(12): 2425-2435 (2006).
114. Chen, P. S., Cha, Y. M., Peters, B. B. and Chen, L. S.: Effects of Myocardial Fiber Orientation on the Electrical Induction of Ventricular-Fibrillation. American Journal of Physiology, 264(6): H1760-H1773 (1993).
115. Dillon, J. S., Gu, X. H. and Nayler, W. G.: Alpha-1 Adrenoceptors in the Ischemic and Reperfused Myocardium. Journal of Molecular and Cellular Cardiology, 20(8): 725-735 (1988).
116. Bauman, J. L.: The role of pharmacokinetics, drug interactions and pharmacogenetics in the acquired long QT syndrome. European Heart Journal Supplements, 3(K): K93-K100 (2001).
117. Bottino, D., Penland, R. C., Stamps, A., Traebert, M., Dumotier, D., Georgieva, A., Helmlinger, G. and Lett, G. S.: Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart. Progress in Biophysics & Molecular Biology, 90(1-3): 414-443 (2006).
118. Colatsky, T. J., Follmer, C. H. and Starmer, C. F.: Channel Specificity in Antiarrhythmic Drug-Action-Mechanism of Potassium Channel Block and Its Role in Suppressing and Aggravating Cardiac-Arrhythmias. Circulation, 82(6): 2235-2242 (1990).
119. Starmer, C. F., Lastra, A. A., Nesterenko, V. V. and Grant, A. O.: Proarrhythmic Response to Sodium-Channel Blockade-Theoretical-Model and Numerical Experiments. Circulation, 84(3): 1364-1377 (1991).
120. Starmer, C. F.: How antiarrhythmic drugs increase the rate of sudden cardiac death. International Journal of Bifurcation and Chaos, 12(9): 1953-1968 (2002).
121. Qu, Z. L., Garfinkel, A. and Weiss, J. N.: Vulnerable window for conduction block in a one-dimensional cable of cardiac cells, 1: Single extrasystoles. Biophysical Journal, 91(3): 793-804 (2006).
122. Weiss, J. N., Garfinkel, A. and Chen, P. S.: Novel approaches antiarrhythmic to identifying drugs. Trends in Cardiovascular Medicine, 13(8): 326-330 (2003).
123. Hondeghem, L. M.: Classification of antiarrhythmic agents and the two laws of pharmacology. Cardiovascular Research, 45(1): 57-60 (2000).
124. Weiss, J. N., Garfinkel, A., Karagueuzian, H. S., Qu, Z. L. and Chen, P. S.: Chaos and the transition to ventricular fibrillation-A new approach to antiarrhythmic drug evaluation. Circulation, 99(21): 2819-2826 (1999).
125. Hondeghem, L. M. and Snyders, D. J.: Class-III Antiarrhythmic Agents Have A Lot of Potential But A Long Way to Go-Reduced Effectiveness and Dangers of Reverse Use Dependence. Circulation, 81(22): 686-690 (1990).
126. Hondeghem, L. M. and Katzung, B. G.: Antiarrhythmic Agents-the Modulated Receptor Mechanism of Action of Sodium and Calcium Channel-Blocking Drugs. Annual Review of Pharmacology and Toxicology, 24: 387-423 (1984).
127. Hondeghem, L. M. and Katzung, B. G.: Time-Dependent and Voltage-Dependent Interactions of Antiarrhythmic Drugs with Cardiac Sodium Channels. Biochimica et Biophysica Acta, 472(3-4): 373-398 (1977).
128. Huffaker, R., Lamp, S. T., Weiss, J. N. and Kogan, B.: Intracellular calcium cycling, early afterdepolarizations, and reentry in simulated long QT syndrome. Heart Rhythm, 1(4): 441-448 (2004).
129. Peitersen, T., Grunnet, M., Benson, A. P., Holden, A. V., Holstein Rathlou, N. H. and Olesen, S. P.: Computational analysis of the effects of the hERG channel opener NS1643 in a human ventricular cell model. Heart Rhythm, 5(5): 734-741 (2008).
130. Spach, M. S., Dolber, P. C., Heidlage, J. F., Kootsey, J. M. and Johnson, E. A.: Propagating Depolarization in Anisotropic Human and Canine Cardiac-Muscle-Apparent Directional Differences in Membrane Capacitance-A Simplified Model for Selective Directional Effects of Modifying the Sodium Conductance on Vmax, Tau-Foot, and the Propagation Safety Factor. Circulation Research, 60(2): 206-219 (1987).
131. Spach, M. S. and Kootsey, J. M.: The Nature of Electrical Propagation in Cardiac-Muscle. American Journal of Physiology, 244(1): H3-H22 (1983).
132. Weis,s D. L., Keller, D. U. J., Seemann, G. and Dossel, O.: The influence of fibre orientation, extracted from different segments of the human left ventricle, on the activation and repolarization sequence: a simulation study. Europace, 9: 96-104 (2007).
133. Hsu, E. W.,Muzikant, A. L.,Matulevicius, S. A., Penland, R. C. and Henriquez, C. S.: Magnetic resonance myocardial fiberorientation mapping with direct histological correlation. American Journal of Physiology-Heart and Circulatory Physiology, 43(5): H1627-H1634 (1998).
134. Guerard, N., Traebert, M., Suter, W. and Dumotier, B. M.: Selective block of IKs plays a significant role in MAP triangulation induced by IKr block in isolated rabbit heart. J. Pharmacol. Toxicol Methods, 58(1): 32-40 (2008).
135. Huffaker, R. B., Samade, R., Weiss, J. N. and Kogan, B.: Tachycardia-induced early afterdepolarizations: Insights into potential ionic mechanisms from computer simulations. Computers in Biology and MedicineIn Press, Corrected Proof.
136. Viswanathan, P. C. and Rudy, Y.: Pause induced early after-depolarizations in the long QT syndrome: a simulation study. Cardiovascular Research, 42(2): 530-542 (1999).
137. Clancy, C. E. and Rudy, Y.: Linking a genetic defect to its cellular phenotype in a cardiac arrhythmia. Nature, 400(6744): 566-569 (1999).
138. Clancy, C. E. and Rudy, Y.: Cellular consequences of HERG mutations in the long QT syndrome: precursors to sudden cardiac death. Cardiovascular Research, 50(2): 301-313 (2001).
139. Tanskanen, A. J., Greenstein, J. L., O'Rourke, B. and Winslow, R. L.: The role of stochastic and modal gating of cardiac L-type Ca2+ channels on early after-depolarizations. Biophysical Journal, 88(1): 85-95 (2005).
140. Grant, A. O. and Tranquillo, J.: Action potential and QT prolongation not sufficient to cause Torsade de Pointes: Role of action potential triangulation. Journal of Cardiovascular Electrophysiology, 18(2): 204-205 (2007).
141. Tsujimae, K., Suzuki, S., Murakami, S. and Kurachi, Y.: Frequency dependent effects of various I-Kr blockers on cardiac action potential duration in a human atrial model. American Journal of Physiology-Heart and Circulatory Physiology, 293(1): H660-H669 (2007).
142. Garfinkel, A.: Eight (or more) kinds of alternans. Journal of Electrocardiology, 40(6): S70-S74 (2007).
143. Suzuki, S., Murakami, S., Tsujimae, K., Findlay, I. and Kurachi, Y.: In silico risk assessment for drug-induction of cardiac arrhythmia. Progress in Biophysics & Molecular Biology, 98(1): 52-60 (2008).
144. Franzone, P. C., Pavarino, L. F. and Taccardi, B.: Effects of transmural electrical heterogeneities and electrotonic interactions on the dispersion of cardiac repolarization and action potential duration: A simulation study. Mathematical Biosciences, 204(1): 132-165 (2006).
145. Franzone, P. C., Pavarino, L. F., Scacchi, S. and Taccardi, B.: Modeling ventricular repolarization: Effects of transmural and apex-to-base heterogeneities in action potential durations. Mathematical Biosciences, 214(1-2): 140-152 (2008).
146. Yang,M. J., Tran, D. X.,Weiss, J. N., Garfinkel, A. and Qu, Z. L.: The pinwheel experiment revisited: effects of cellular electrophysiological properties on vulnerability to cardiac reentry. American Journal of Physiology-Heart and Circulatory Physiology, 293(3): H1781-H1790 (2007).
147. Samie, F. H., Mandapati, R., Gray, R. A., Watanabe, Y., Zuur, C., Beaumont, J. and Jalife, J.: A mechanism of transition from ventricular fibrillation to tachycardia - Effect of calcium channel blockade on the dynamics of rotating waves. Circulation Research, 86(6): 684-691 (2000).
148. van Oosterom, A. and Jacquemet, V.: Genesis of the P wave: Atrial signals as generated by the equivalent double layer source model. Europace, 7: S21-S29 (2005).
149. van Oosterom, A.: The dominant T wave and its significance. Journal of Cardiovascular Electrophysiology, 14(10): S180-S187 (2003).
150. di Bernardo D, Murray A. Modelling cardiac repolarisation for the study of the T wave: effect of repolarisation sequence. Chaos Solitons & Fractals, 13(8): 1743-1748 (2002).
151. Gima, K. and Rudy, Y.: Ionic current basis of electrocardiographic waveforms - A model study. Circulation Research, 90(8): 889-896 (2002).
152. di Bernardo, D. and Murray, A.: Computer model for study of cardiac repolarization. Journal of Cardiovascular Electrophysiology, 11(8): 895-899 (2000).
153. di Bernardo, D. and Murray, A.: Medical physics-Explaining the T-wave shape in the ECG. Nature, 403(6765): 40 (2000).